ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANAB is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has strong analyst support, multiple recent price target increases, and a clear catalyst in the upcoming GSK dispute court date, which could materially benefit the royalty business. With no adverse insider, politician, or congress trading signals and no negative options signal available, the setup is constructive. Since the user is unwilling to wait for a better entry, the current evidence favors buying rather than holding back.
No stock trend data was available due to an error fetching trend data, so a precise chart-based trend read is limited. Still, the stock appears to have strong upward momentum implied by repeated analyst target raises and comments that it has traded up about 190% over the last year. That suggests a sustained bullish trend rather than a weak or deteriorating one. In the absence of direct price/indicator data, the technical picture is best interpreted as positive bias with trend support, though not confirmable from the supplied data.
["Leerink raised its price target to $90 and maintained an Outperform rating, citing a bullish view ahead of the July 14-17 GSK dispute court date.", "UBS raised its price target to $76 and kept a Buy rating.", "Barclays raised its price target to $75 and kept an Overweight rating.", "Piper Sandler remains constructive, highlighting that the post-spinoff structure better protects and optimizes royalty value.", "AnaptysBio is now a pure-play royalty company with accelerating Jemperli cash flows.", "Potential positive resolution in the GSK dispute could unlock additional value."]
["Q1 Jemperli collaboration revenue came in below expectations.", "Some analysts did lower price targets earlier in April, showing valuation expectations are not uniformly rising.", "The company is now more dependent on royalty and legal outcomes after the TRAX spinoff, increasing event-dependence."]
The latest quarter referenced is Q1 2026. Financial commentary was mixed: Jemperli collaboration revenue was below expectations, but analysts still emphasized the improving royalty stream and accelerating Jemperli cash flows. The company’s post-spinoff profile is now more focused on recurring royalty economics rather than broad biotech development, which supports a clearer long-term growth narrative if Jemperli continues to scale.
Analyst sentiment is clearly positive overall. Recent actions included Leerink raising its target to $90 from $85 with Outperform, UBS raising to $76 from $60 with Buy, Barclays raising to $75 from $63 with Overweight, and Piper Sandler lifting its target to $93 before trimming it to $93 from $95 while still Overweight. The overall Wall Street view is bullish: pros like the streamlined royalty model, strong Jemperli momentum, and potential upside from the GSK dispute. The main con is that some upside is tied to legal/event outcomes and recent revenue was a bit softer than expected, but the consensus tone remains favorable.
